Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook

Thelansis’s “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Inflammatory Demyelinating Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neuropathic condition affecting peripheral nerves and nerve roots. It is acquired and mediated by the immune system, typically presenting with recurring or progressively worsening symmetrical weakness in both proximal and distal muscle groups. Clinically, CIDP is divided into two categories: "typical" and "atypical" cases. Typical CIDP manifests as a symmetrical polyneuropathy, equally impacting both proximal and distal muscles. In contrast, atypical CIDP includes conditions like 'distal acquired demyelinating symmetric' (DADS) and multifocal acquired demyelinating sensory and motor neuropathy (MADSAM), also known as Lewis-Sumner syndrome (LSS). DADS is characterized by a symmetrical, length-dependent sensory or sensorimotor neuropathy, often associated with an IgM paraprotein and significantly increased distal motor latencies. While these features resemble demyelinating neuropathy with antibodies against myelin-associated glycoprotein (MAG), anti-MAG neuropathy is excluded from CIDP according to EFNS/PNS criteria due to the presence of specific antibody presence and distinct treatment responses. LSS exhibits a multifocal distribution; a key electrophysiological feature is a conduction block. Additionally, pure motor and sensory CIDP variants have been documented, with some cases restricted to sensory nerve roots, referred to as chronic immune sensory polyradiculopathy. CIDP is diagnosed based on electrodiagnostic or pathological evidence of demyelination and a positive response to immunomodulatory therapies. The most common subtype is typical CIDP, accounting for at least 50 to 60 percent of all cases. Panzyga® (Immune Globulin Intravenous [Human] – 10 percent Liquid Preparation) treats adults with CIDP, a neurological disorder affecting the peripheral nerves.

• The estimated annual incidence of CIDP in the USA is 8.9 cases per 100,000 individuals. This condition is more commonly observed in male patients, with a male-to-female ratio of 2:1, and it tends to be more prevalent among older individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: